Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 15/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 14/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247469 | 0.77 | OPRL1 (0.48) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL2240983 | 0.77 | OPRL1 (0.48) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL1711157 | 0.72 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL25736629 | 0.72 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL1711153 | 0.72 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL29408438 | 0.72 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL15861075 | 0.71 | OPRM1 (0.60) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL15861264 | 0.71 | OPRM1 (0.60) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL15861063 | 0.71 | OPRM1 (0.60) | OPRL1OPRM1OPRK1OPRD1 | |
| Hydrochloric Acid SCHEMBL22408650 | 0.70 | OPRL1 (0.96) | OPRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2394997-A1 | PROCESS FOR PREPARING 1-(4-PIPERIDINYL)BENZIMIDAZOLONE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-12-14 | — | — | EP | disclosed |
| EP-2394997-A1 | PROCESS FOR PREPARING 1-(4-PIPERIDINYL)BENZIMIDAZOLONE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110295013-A1 | PROCESS FOR PREPARING 1-(4-PIPERIDINYL)BENZIMIDAZOLONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-01 | — | — | US | disclosed |
| US-20110295013-A1 | PROCESS FOR PREPARING 1-(4-PIPERIDINYL)BENZIMIDAZOLONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295013-A1 | PROCESS FOR PREPARING 1-(4-PIPERIDINYL)BENZIMIDAZOLONE DERIVATIVES | HDAC4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC2 | OPRL1 4449/4885OPRM1 3420/4885OPRK1 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.